VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,470 | +2.1% | 1,500 | 0.0% | 0.01% | +10.0% |
| Q2 2023 | $74,910 | +33.2% | 1,500 | 0.0% | 0.01% | +42.9% |
| Q1 2023 | $56,220 | -21.8% | 1,500 | 0.0% | 0.01% | -36.4% |
| Q4 2022 | $71,925 | +99.8% | 1,500 | 0.0% | 0.01% | +83.3% |
| Q3 2022 | $36,000 | +9.1% | 1,500 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $33,000 | -8.3% | 1,500 | 0.0% | 0.01% | +20.0% |
| Q1 2022 | $36,000 | 0.0% | 1,500 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $36,000 | -5.3% | 1,500 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $38,000 | – | 1,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |